[Systemic sclerosis. Objectives for the treatment].

Zeitschrift für Rheumatologie
B MaurerO Distler

Abstract

Systemic sclerosis (SSc) is a multi-systemic fibrotic disorder with worldwide distribution and high morbidity and mortality. Characteristic features of this disease are widespread vasculopathy, inflammation, autoimmunity, and fibrosis. The better clinical outcome in recent years is mainly due to better management of organ complications. To date, there is no approved specific therapy to prevent or slow down the overall progression of the disease. So far, conventional disease-modifying antirheumatic drugs (DMARDs) have had no major impact on the disease course and have not prolonged survival. Based on recent studies of molecular pathomechanisms and various animal models, key molecules of fibrogenesis and vasculopathy in SSc could be identified. Therefore, to date, we have to reconsider and redefine the objectives of our treatment strategies. In this article, we discuss current and future therapeutic concepts as well as the objectives of new treatment strategies and of the evaluation of diagnostic tools with respect to pulmonary arterial hypertension, lung fibrosis and skin/systemic fibrosis.

References

Apr 1, 1986·Arthritis and Rheumatism·A M StupiT A Medsger
Sep 1, 1994·Arthritis and Rheumatism·V D SteenT A Medsger
Feb 12, 2004·Arthritis and Rheumatism·Maureen D MayesM E Csuka
Jul 14, 2004·Chest·Vallerie V McLaughlinUNKNOWN American College of Chest Physicians
Dec 17, 2005·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Virginia D Steen
Jun 23, 2006·The New England Journal of Medicine·Donald P TashkinUNKNOWN Scleroderma Lung Study Research Group
Mar 3, 2007·Annals of the Rheumatic Diseases·Virginia D Steen, Thomas A Medsger
Mar 3, 2007·The Journal of Clinical Investigation·John Varga, David Abraham
Aug 25, 2007·American Journal of Respiratory and Critical Care Medicine·Donald P TashkinUNKNOWN Scleroderma Lung Study Research Group
Oct 27, 2007·Seminars in Hematology·Jakob Passweg, Alan Tyndall
Mar 29, 2008·American Journal of Respiratory and Critical Care Medicine·Nicole S L GohAthol U Wells
Apr 29, 2008·Arthritis and Rheumatism·Peter A MerkelUNKNOWN Scleroderma Clinical Trials Consortium
Aug 1, 2008·Arthritis and Rheumatism·Jörg H W DistlerOliver Distler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia Cerebrovascular Disease

Basal ganglia cerebrovascular disease is a condition where the blood vessels in the basal ganglia are damaged or malfunction. Discover the latest research on basal ganglia cerebrovascular disease here.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Best Practice & Research. Clinical Rheumatology
B Maurer, O Distler
The Journal of Clinical Investigation
John Varga, D J Abraham
Seminars in Cutaneous Medicine and Surgery
J H Stone, F M Wigley
Rheumatology
G Riemekasten, C Sunderkötter
© 2021 Meta ULC. All rights reserved